A strong H1 trading performance gives us increased confidence in our FY expectations. We have considered a slight upgrade to expectations; however, uncertainty over the impact of the recent high profile storms in the company’s South-Western US region leads us to be prudent at this stage. Overall, ClearStar continues to trade just below breakeven at an EBITDA level, while steadily building revenue from a move to direct sales, particularly in the medical market. Future growth will be assi
19 Sep 2017
Record H1 driven by direct sales and medical business
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Record H1 driven by direct sales and medical business
- Published:
19 Sep 2017 -
Author:
Cavendish Research -
Pages:
8
A strong H1 trading performance gives us increased confidence in our FY expectations. We have considered a slight upgrade to expectations; however, uncertainty over the impact of the recent high profile storms in the company’s South-Western US region leads us to be prudent at this stage. Overall, ClearStar continues to trade just below breakeven at an EBITDA level, while steadily building revenue from a move to direct sales, particularly in the medical market. Future growth will be assi